Yeatman T J
Department of Surgery, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Surg Oncol Clin N Am. 1995 Oct;4(4):569-89.
Breast cancer is considered a chronic disease in most women. This belief is based on natural history data that suggest that some patients with untreated, advanced disease may survive for up to and beyond 20 years after diagnosis. These data are corroborated by studies of treated patients in whom breast cancer recurred up to 15 to 20 years postmastectomy. Conversely, there are also patients who die rapidly after presentation. These divergent observations suggest that there are at least two subpopulations of patients with breast cancer-one that co-exists with the disease and one that rapidly succumbs to it. This heterogeneous biologic behavior is likely related to divergent tumor cell growth rates that have been documented as well as to other unidentified factors. These two subsets of patients, unfortunately, are quite difficult to distinguish. With the promise of the ongoing genetic revolution, the hope is that genes associated with rapidly progressing disease states can be identified. It is important to be cognizant of the prolonged natural history of this disease whenever we attempt to draw conclusions regarding a promising new treatment and we must make every attempt to ensure that patients are improving because of, rather than despite, a therapeutic intervention. Patients entered into trials examining survival as an endpoint should make every attempt to follow patients for 20 to 30 years after treatment. These considerations will ensure that patients requiring therapy are treated to derive benefit, whereas those who would normally not benefit or fare just as well without treatment are not exposed to unnecessary morbidity and mortality. Finally, it must be concluded as Bloom et al have stated that "the value of treatment of primary breast cancer cannot be measured entirely by survival statistics." The quality of a patient's remaining life once the diagnosis of breast cancer has been made should be considered. From untreated natural history data, we know that patients may suffer a painful death without intervention, and we are aware as well that overtreatment may impart untoward symptomatic consequences in the final stages of life when quality is of paramount importance to both the patient and the family.
在大多数女性中,乳腺癌被视为一种慢性病。这一观点基于自然病史数据,这些数据表明,一些未经治疗的晚期乳腺癌患者在确诊后可能存活长达20年甚至更久。乳房切除术后15至20年乳腺癌复发的接受治疗患者的研究也证实了这些数据。相反,也有一些患者在确诊后很快死亡。这些不同的观察结果表明,至少有两个乳腺癌患者亚群——一个与疾病共存,另一个则迅速死于该病。这种异质性的生物学行为可能与已记录的不同肿瘤细胞生长速率以及其他未明确的因素有关。不幸的是,这两类患者很难区分。随着当前基因革命带来的希望,人们期望能够识别出与疾病快速进展状态相关的基因。每当我们试图就一种有前景的新疗法得出结论时,认识到这种疾病漫长的自然病史很重要,而且我们必须尽一切努力确保患者是因为治疗干预而有所改善,而非尽管接受了治疗却没有改善。参加以生存为终点的试验的患者,应尽一切努力在治疗后对患者进行20至30年的随访。这些考虑将确保需要治疗的患者得到治疗以获得益处,而那些通常无需治疗也不会受益或病情同样良好的患者不会遭受不必要的发病和死亡。最后,正如布鲁姆等人所说,必须得出结论:“原发性乳腺癌治疗的价值不能完全通过生存统计数据来衡量。”一旦确诊乳腺癌,患者剩余生命的质量也应予以考虑。从未经治疗的自然病史数据中,我们知道患者若不进行干预可能会痛苦地死去,而且我们也意识到过度治疗可能在生命的最后阶段带来不良的症状后果,而此时生命质量对患者和家属都至关重要。